• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

    3/1/22 10:04:17 AM ET
    $ACLX
    $ACVA
    $ALNY
    $AMED
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Real Estate
    Get the next $ACLX alert in real time by email

    Upgrades

    Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71, compared to year-ago quarter EPS of $0.52. The stock has a 52-week-high of $50.88 and a 52-week-low of $18.07. At the end of the last trading period, Revolution Medicines closed at $18.92.

    According to UBS, the prior rating for Amedisys Inc (NASDAQ:AMED) was changed from Sell to Neutral. For the fourth quarter, Amedisys had an EPS of $1.18, compared to year-ago quarter EPS of $1.49. At the moment, the stock has a 52-week-high of $292.97 and a 52-week-low of $122.12. Amedisys closed at $160.24 at the end of the last trading period.

    For Sunstone Hotel Investors Inc (NYSE:SHO), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. At the moment, the stock has a 52-week-high of $13.91 and a 52-week-low of $9.93. Sunstone Hotel Invts closed at $10.58 at the end of the last trading period.

    Wedbush upgraded the previous rating for Logitech International SA (NASDAQ:LOGI) from Neutral to Outperform. In the third quarter, Logitech International showed an EPS of $1.55, compared to $2.45 from the year-ago quarter. The stock has a 52-week-high of $140.17 and a 52-week-low of $69.92. At the end of the last trading period, Logitech International closed at $74.64.

    For Farfetch Ltd (NYSE:FTCH), Societe Generale upgraded the previous rating of Sell to Hold. Farfetch earned $0.03 in the fourth quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $67.71 and a 52-week-low of $12.36. Farfetch closed at $19.05 at the end of the last trading period.

    According to B. Riley Securities, the prior rating for Quanta Services Inc (NYSE:PWR) was changed from Neutral to Buy. In the fourth quarter, Quanta Servs showed an EPS of $1.54, compared to $1.22 from the year-ago quarter. The current stock performance of Quanta Servs shows a 52-week-high of $124.69 and a 52-week-low of $78.79. Moreover, at the end of the last trading period, the closing price was at $108.94.

    For Jack Henry & Associates Inc (NASDAQ:JKHY), Oppenheimer upgraded the previous rating of Perform to Outperform. Jack Henry & Associates earned $1.30 in the second quarter, compared to $0.92 in the year-ago quarter. The stock has a 52-week-high of $179.98 and a 52-week-low of $146.10. At the end of the last trading period, Jack Henry & Associates closed at $176.80.

    For Lennox International Inc (NYSE:LII), Morgan Stanley upgraded the previous rating of Underweight to Equal-Weight. Lennox International earned $2.35 in the fourth quarter, compared to $2.89 in the year-ago quarter. At the moment, the stock has a 52-week-high of $356.36 and a 52-week-low of $243.92. Lennox International closed at $266.93 at the end of the last trading period.

    For Advanced Drainage Systems Inc (NYSE:WMS), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Advanced Drainage Systems showed an EPS of $0.86, compared to $0.62 from the year-ago quarter. At the moment, the stock has a 52-week-high of $138.02 and a 52-week-low of $93.66. Advanced Drainage Systems closed at $116.72 at the end of the last trading period.

    See all analyst ratings upgrades.

    Downgrades

    According to Tudor Pickering, the prior rating for Cactus Inc (NYSE:WHD) was changed from Buy to Hold. For the fourth quarter, Cactus had an EPS of $0.25, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $51.51 and a 52-week-low of $27.26. At the end of the last trading period, Cactus closed at $50.66.

    According to Janney Montgomery Scott, the prior rating for First Horizon Corp (NYSE:FHN) was changed from Buy to Neutral. First Horizon earned $0.48 in the fourth quarter, compared to $0.46 in the year-ago quarter. The current stock performance of First Horizon shows a 52-week-high of $24.24 and a 52-week-low of $14.67. Moreover, at the end of the last trading period, the closing price was at $23.48.

    According to Craig-Hallum, the prior rating for Velodyne Lidar Inc (NASDAQ:VLDR) was changed from Hold to Sell. In the fourth quarter, Velodyne Lidar showed an EPS of $0.16, compared to $0.12 from the year-ago quarter. The stock has a 52-week-high of $17.20 and a 52-week-low of $3.13. At the end of the last trading period, Velodyne Lidar closed at $3.69.

    According to Truist Securities, the prior rating for Comcast Corp (NASDAQ:CMCSA) was changed from Buy to Hold. Comcast earned $0.77 in the fourth quarter, compared to $0.56 in the year-ago quarter. At the moment, the stock has a 52-week-high of $61.80 and a 52-week-low of $44.27. Comcast closed at $46.76 at the end of the last trading period.

    For Voya Financial Inc (NYSE:VOYA), Piper Sandler downgraded the previous rating of Overweight to Neutral. In the fourth quarter, Voya Financial showed an EPS of $1.90, compared to $1.44 from the year-ago quarter. The stock has a 52-week-high of $74.97 and a 52-week-low of $58.97. At the end of the last trading period, Voya Financial closed at $67.35.

    According to Piper Sandler, the prior rating for Ameriprise Financial Inc (NYSE:AMP) was changed from Overweight to Neutral. In the fourth quarter, Ameriprise Financial showed an EPS of $6.15, compared to $4.53 from the year-ago quarter. The current stock performance of Ameriprise Financial shows a 52-week-high of $332.37 and a 52-week-low of $213.38. Moreover, at the end of the last trading period, the closing price was at $299.79.

    For Charter Communications Inc (NASDAQ:CHTR), Truist Securities downgraded the previous rating of Buy to Hold. In the fourth quarter, Charter Communications showed an EPS of $8.93, compared to $6.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $825.62 and a 52-week-low of $549.59. Charter Communications closed at $601.78 at the end of the last trading period.

    According to Stifel, the prior rating for Pennant Group Inc (NASDAQ:PNTG) was changed from Buy to Hold. In the fourth quarter, Pennant Group showed an EPS of $0.07, compared to $0.17 from the year-ago quarter. At the moment, the stock has a 52-week-high of $58.21 and a 52-week-low of $12.94. Pennant Group closed at $16.25 at the end of the last trading period.

    According to William Blair, the prior rating for ON24 Inc (NYSE:ONTF) was changed from Outperform to Market Perform. For the fourth quarter, ON24 had an EPS of $0.03, compared to year-ago quarter EPS of $0.57. At the moment, the stock has a 52-week-high of $64.50 and a 52-week-low of $14.03. ON24 closed at $15.60 at the end of the last trading period.

    Cowen & Co. downgraded the previous rating for GoodRx Holdings Inc (NASDAQ:GDRX) from Outperform to Market Perform. For the fourth quarter, GoodRx Holdings had an EPS of $0.09, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $48.05 and a 52-week-low of $21.13. At the end of the last trading period, GoodRx Holdings closed at $27.40.

    For Turtle Beach Corp (NASDAQ:HEAR), Wedbush downgraded the previous rating of Outperform to Neutral. For the third quarter, Turtle Beach had an EPS of $0.26, compared to year-ago quarter EPS of $1.05. The stock has a 52-week-high of $38.70 and a 52-week-low of $17.03. At the end of the last trading period, Turtle Beach closed at $23.77.

    B of A Securities downgraded the previous rating for Viatris Inc (NASDAQ:VTRS) from Buy to Neutral. In the fourth quarter, Viatris showed an EPS of $0.80, compared to $1.07 from the year-ago quarter. At the moment, the stock has a 52-week-high of $16.29 and a 52-week-low of $10.88. Viatris closed at $11.01 at the end of the last trading period.

    According to Raymond James, the prior rating for Viatris Inc (NASDAQ:VTRS) was changed from Outperform to Market Perform. Viatris earned $0.80 in the fourth quarter, compared to $1.07 in the year-ago quarter. The stock has a 52-week-high of $16.29 and a 52-week-low of $10.88. At the end of the last trading period, Viatris closed at $11.01.

    For Sunstone Hotel Investors Inc (NYSE:SHO), Barclays downgraded the previous rating of Overweight to Underweight. The stock has a 52-week-high of $13.91 and a 52-week-low of $9.93. At the end of the last trading period, Sunstone Hotel Invts closed at $10.58.

    For Foot Locker Inc (NYSE:FL), Barclays downgraded the previous rating of Overweight to Underweight. In the fourth quarter, Foot Locker showed an EPS of $1.67, compared to $1.55 from the year-ago quarter. The current stock performance of Foot Locker shows a 52-week-high of $66.71 and a 52-week-low of $26.36. Moreover, at the end of the last trading period, the closing price was at $31.62.

    According to Citigroup, the prior rating for Meritor Inc (NYSE:MTOR) was changed from Buy to Neutral. For the first quarter, Meritor had an EPS of $0.80, compared to year-ago quarter EPS of $0.60. At the moment, the stock has a 52-week-high of $36.24 and a 52-week-low of $20.50. Meritor closed at $35.61 at the end of the last trading period.

    Citigroup downgraded the previous rating for BP Midstream Partners LP (NYSE:BPMP) from Neutral to Sell. In the third quarter, BP Midstream Partners showed an EPS of $0.27, compared to $0.42 from the year-ago quarter. The current stock performance of BP Midstream Partners shows a 52-week-high of $19.37 and a 52-week-low of $11.01. Moreover, at the end of the last trading period, the closing price was at $16.63.

    Wells Fargo downgraded the previous rating for Vroom Inc (NASDAQ:VRM) from Overweight to Equal-Weight. In the fourth quarter, Vroom showed an EPS of $0.94, compared to $0.44 from the year-ago quarter. The current stock performance of Vroom shows a 52-week-high of $49.03 and a 52-week-low of $5.10. Moreover, at the end of the last trading period, the closing price was at $6.08.

    B. Riley Securities downgraded the previous rating for Foot Locker Inc (NYSE:FL) from Buy to Neutral. In the fourth quarter, Foot Locker showed an EPS of $1.67, compared to $1.55 from the year-ago quarter. The current stock performance of Foot Locker shows a 52-week-high of $66.71 and a 52-week-low of $26.36. Moreover, at the end of the last trading period, the closing price was at $31.62.

    Raymond James downgraded the previous rating for First Horizon Corp (NYSE:FHN) from Outperform to Market Perform. First Horizon earned $0.48 in the fourth quarter, compared to $0.46 in the year-ago quarter. At the moment, the stock has a 52-week-high of $24.24 and a 52-week-low of $14.67. First Horizon closed at $23.48 at the end of the last trading period.

    For Gemini Therapeutics Inc (NASDAQ:GMTX), Jefferies downgraded the previous rating of Buy to Hold. The stock has a 52-week-high of $19.09 and a 52-week-low of $1.36. At the end of the last trading period, Gemini Therapeutics closed at $1.36.

    Credit Suisse downgraded the previous rating for GoodRx Holdings Inc (NASDAQ:GDRX) from Outperform to Neutral. For the fourth quarter, GoodRx Holdings had an EPS of $0.09, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $48.05 and a 52-week-low of $21.13. At the end of the last trading period, GoodRx Holdings closed at $27.40.

    Baird downgraded the previous rating for ON24 Inc (NYSE:ONTF) from Outperform to Neutral. In the fourth quarter, ON24 showed an EPS of $0.03, compared to $0.57 from the year-ago quarter. The stock has a 52-week-high of $64.50 and a 52-week-low of $14.03. At the end of the last trading period, ON24 closed at $15.60.

    For Wix.com Ltd (NASDAQ:WIX), Atlantic Equities downgraded the previous rating of Overweight to Neutral. In the fourth quarter, Wix.com showed an EPS of $0.37, compared to $0.03 from the year-ago quarter. At the moment, the stock has a 52-week-high of $361.62 and a 52-week-low of $77.64. Wix.com closed at $91.58 at the end of the last trading period.

    Piper Sandler downgraded the previous rating for ON24 Inc (NYSE:ONTF) from Overweight to Neutral. ON24 earned $0.03 in the fourth quarter, compared to $0.57 in the year-ago quarter. The stock has a 52-week-high of $64.50 and a 52-week-low of $14.03. At the end of the last trading period, ON24 closed at $15.60.

    Goldman Sachs downgraded the previous rating for Lincoln National Corp (NYSE:LNC) from Buy to Neutral. For the fourth quarter, Lincoln National had an EPS of $1.56, compared to year-ago quarter EPS of $1.78. The current stock performance of Lincoln National shows a 52-week-high of $77.57 and a 52-week-low of $55.01. Moreover, at the end of the last trading period, the closing price was at $67.42.

    For Foot Locker Inc (NYSE:FL), Goldman Sachs downgraded the previous rating of Buy to Neutral. In the fourth quarter, Foot Locker showed an EPS of $1.67, compared to $1.55 from the year-ago quarter. The stock has a 52-week-high of $66.71 and a 52-week-low of $26.36. At the end of the last trading period, Foot Locker closed at $31.62.

    See all analyst ratings downgrades.

    Initiations

    Guggenheim initiated coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a Buy rating. The price target for Ionis Pharmaceuticals is set to $64.00. For the fourth quarter, Ionis Pharmaceuticals had an EPS of $1.55, compared to year-ago quarter EPS of $0.81. The stock has a 52-week-high of $56.01 and a 52-week-low of $25.04. At the end of the last trading period, Ionis Pharmaceuticals closed at $33.38.

    With an Overweight rating, Piper Sandler initiated coverage on Silver Spike Investment Corp (NASDAQ:SSIC). The price target seems to have been set at $17.00 for Silver Spike Inv. The current stock performance of Silver Spike Inv shows a 52-week-high of $15.40 and a 52-week-low of $13.30. Moreover, at the end of the last trading period, the closing price was at $14.17.

    With an Outperform rating, SVB Leerink initiated coverage on Arcellx Inc (NASDAQ:ACLX). The price target seems to have been set at $47.00 for Arcellx. The current stock performance of Arcellx shows a 52-week-high of $19.93 and a 52-week-low of $15.55. Moreover, at the end of the last trading period, the closing price was at $19.14.

    With a Buy rating, Needham initiated coverage on ACV Auctions Inc (NASDAQ:ACVA). The price target seems to have been set at $20.00 for ACV Auctions. At the moment, the stock has a 52-week-high of $37.77 and a 52-week-low of $10.30. ACV Auctions closed at $13.19 at the end of the last trading period.

    With a Buy rating, Ladenburg Thalmann initiated coverage on Onconova Therapeutics Inc (NASDAQ:ONTX). The price target seems to have been set at $7.00 for Onconova Therapeutics. Onconova Therapeutics earned $0.22 in the third quarter, compared to $0.45 in the year-ago quarter. The current stock performance of Onconova Therapeutics shows a 52-week-high of $10.84 and a 52-week-low of $0.49. Moreover, at the end of the last trading period, the closing price was at $1.62.

    With a Buy rating, Ladenburg Thalmann initiated coverage on NextCure Inc (NASDAQ:NXTC). The price target seems to have been set at $16.00 for NextCure. For the third quarter, NextCure had an EPS of $0.65, compared to year-ago quarter EPS of $0.59. The stock has a 52-week-high of $12.98 and a 52-week-low of $4.63. At the end of the last trading period, NextCure closed at $4.90.

    B of A Securities initiated coverage on Arcellx Inc (NASDAQ:ACLX) with a Buy rating. The price target for Arcellx is set to $24.00. The current stock performance of Arcellx shows a 52-week-high of $19.93 and a 52-week-low of $15.55. Moreover, at the end of the last trading period, the closing price was at $19.14.

    Benchmark initiated coverage on Pinterest Inc (NYSE:PINS) with a Hold rating. For the fourth quarter, Pinterest had an EPS of $0.49, compared to year-ago quarter EPS of $0.43. At the moment, the stock has a 52-week-high of $88.83 and a 52-week-low of $22.31. Pinterest closed at $26.75 at the end of the last trading period.

    Benchmark initiated coverage on Twitter Inc (NYSE:TWTR) with a Hold rating. For the fourth quarter, Twitter had an EPS of $0.33, compared to year-ago quarter EPS of $0.38. The stock has a 52-week-high of $79.08 and a 52-week-low of $31.30. At the end of the last trading period, Twitter closed at $35.55.

    Benchmark initiated coverage on Snap Inc (NYSE:SNAP) with a Buy rating. The price target for Snap is set to $50.00. For the fourth quarter, Snap had an EPS of $0.22, compared to year-ago quarter EPS of $0.09. The current stock performance of Snap shows a 52-week-high of $83.34 and a 52-week-low of $24.32. Moreover, at the end of the last trading period, the closing price was at $39.94.

    For The Trade Desk Inc (NASDAQ:TTD), Benchmark initiated coverage, by setting the current rating at Hold. Trade Desk earned $0.42 in the fourth quarter, compared to $0.37 in the year-ago quarter. The current stock performance of Trade Desk shows a 52-week-high of $835.00 and a 52-week-low of $55.05. Moreover, at the end of the last trading period, the closing price was at $85.32.

    Benchmark initiated coverage on Criteo SA (NASDAQ:CRTO) with a Buy rating. The price target for Criteo is set to $45.00. Criteo earned $1.44 in the fourth quarter, compared to $0.98 in the year-ago quarter. The stock has a 52-week-high of $46.65 and a 52-week-low of $29.30. At the end of the last trading period, Criteo closed at $33.26.

    For Meta Platforms Inc (NASDAQ:FB), Benchmark initiated coverage, by setting the current rating at Hold. In the fourth quarter, Meta Platforms showed an EPS of $3.67, compared to $3.88 from the year-ago quarter. The stock has a 52-week-high of $384.33 and a 52-week-low of $190.22. At the end of the last trading period, Meta Platforms closed at $211.03.

    Wells Fargo initiated coverage on Taysha Gene Therapies Inc (NASDAQ:TSHA) with an Overweight rating. The price target for Taysha Gene Therapies is set to $25.00. Taysha Gene Therapies earned $1.35 in the third quarter, compared to $1.28 in the year-ago quarter. The current stock performance of Taysha Gene Therapies shows a 52-week-high of $29.90 and a 52-week-low of $5.57. Moreover, at the end of the last trading period, the closing price was at $6.37.

    RBC Capital initiated coverage on MongoDB Inc (NASDAQ:MDB) with an Outperform rating. The price target for MongoDB is set to $505.00. In the third quarter, MongoDB showed an EPS of $0.11, compared to $0.31 from the year-ago quarter. The current stock performance of MongoDB shows a 52-week-high of $590.00 and a 52-week-low of $238.01. Moreover, at the end of the last trading period, the closing price was at $381.99.

    JMP Securities initiated coverage on America First Multifamily Investors LP (NASDAQ:ATAX) with a Market Outperform rating. The price target for America First Multifamily is set to $7.00. America First Multifamily earned $0.11 in the fourth quarter, compared to $0.00 in the year-ago quarter. At the moment, the stock has a 52-week-high of $7.11 and a 52-week-low of $4.56. America First Multifamily closed at $6.48 at the end of the last trading period.

    Citigroup initiated coverage on Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) with a Buy rating. The price target for Alnylam Pharmaceuticals is set to $223.00. Alnylam Pharmaceuticals earned $1.69 in the fourth quarter, compared to $1.60 in the year-ago quarter. At the moment, the stock has a 52-week-high of $212.00 and a 52-week-low of $125.00. Alnylam Pharmaceuticals closed at $157.85 at the end of the last trading period.

    Stifel initiated coverage on Silver Spike Investment Corp (NASDAQ:SSIC) with a Hold rating. The current stock performance of Silver Spike Inv shows a 52-week-high of $15.40 and a 52-week-low of $13.30. Moreover, at the end of the last trading period, the closing price was at $14.17.

    Mizuho initiated coverage on Constellation Energy Corp (NASDAQ:CEG) with a Neutral rating. The price target for Constellation Energy is set to $46.00. The stock has a 52-week-high of $56.57 and a 52-week-low of $42.18. At the end of the last trading period, Constellation Energy closed at $45.98.

    Citigroup initiated coverage on Schrodinger Inc (NASDAQ:SDGR) with a Buy rating. The price target for Schrodinger is set to $55.00. In the fourth quarter, Schrodinger showed an EPS of $0.43, compared to $0.18 from the year-ago quarter. The current stock performance of Schrodinger shows a 52-week-high of $114.10 and a 52-week-low of $23.14. Moreover, at the end of the last trading period, the closing price was at $34.76.

    Citigroup initiated coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a Sell rating. The price target for Ionis Pharmaceuticals is set to $26.00. For the fourth quarter, Ionis Pharmaceuticals had an EPS of $1.55, compared to year-ago quarter EPS of $0.81. The stock has a 52-week-high of $56.01 and a 52-week-low of $25.04. At the end of the last trading period, Ionis Pharmaceuticals closed at $33.38.

    Citigroup initiated coverage on Blueprint Medicines Corp (NASDAQ:BPMC) with a Neutral rating. Blueprint Medicines earned $0.99 in the fourth quarter, compared to $1.53 in the year-ago quarter. At the moment, the stock has a 52-week-high of $117.86 and a 52-week-low of $60.12. Blueprint Medicines closed at $60.55 at the end of the last trading period.

    Citigroup initiated coverage on Ascendis Pharma A/S (NASDAQ:ASND) with a Buy rating. The price target for Ascendis Pharma is set to $187.00. For the third quarter, Ascendis Pharma had an EPS of $1.73, compared to year-ago quarter EPS of $2.70. The stock has a 52-week-high of $178.71 and a 52-week-low of $103.81. At the end of the last trading period, Ascendis Pharma closed at $112.39.

    See all analyst ratings initiations.

    Get the next $ACLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLX
    $ACVA
    $ALNY
    $AMED

    CompanyDatePrice TargetRatingAnalyst
    Snap Inc.
    $SNAP
    2/10/2026$7.30Neutral → Buy
    Arete
    Viatris Inc.
    $VTRS
    2/9/2026$18.00Neutral → Buy
    UBS
    Snap Inc.
    $SNAP
    2/6/2026$5.50Sell → Hold
    Stifel
    Snap Inc.
    $SNAP
    2/5/2026$10.00Neutral → Buy
    BofA Securities
    Jack Henry & Associates Inc.
    $JKHY
    2/5/2026$205.00Neutral → Outperform
    Robert W. Baird
    Jack Henry & Associates Inc.
    $JKHY
    2/5/2026$205.00Equal-Weight → Overweight
    Stephens
    Pinterest Inc.
    $PINS
    1/30/2026$24.90Buy → Hold
    HSBC Securities
    Ameriprise Financial Inc.
    $AMP
    1/30/2026$530.00Underweight → Neutral
    Piper Sandler
    More analyst ratings

    $ACLX
    $ACVA
    $ALNY
    $AMED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Chamoun George bought $123,312 worth of shares (16,892 units at $7.30), increasing direct ownership by 0.58% to 2,928,705 units (SEC Form 4)

    4 - ACV Auctions Inc. (0001637873) (Issuer)

    2/10/26 4:48:21 PM ET
    $ACVA
    Real Estate

    Chief Executive Officer Chamoun George bought $125,860 worth of shares (14,286 units at $8.81), increasing direct ownership by 0.55% to 2,598,383 units (SEC Form 4)

    4 - ACV Auctions Inc. (0001637873) (Issuer)

    1/13/26 4:21:31 PM ET
    $ACVA
    Real Estate

    Chief Executive Officer Chamoun George bought $248,441 worth of shares (31,172 units at $7.97), increasing direct ownership by 1% to 2,618,714 units (SEC Form 4)

    4 - ACV Auctions Inc. (0001637873) (Issuer)

    12/17/25 4:51:58 PM ET
    $ACVA
    Real Estate

    $ACLX
    $ACVA
    $ALNY
    $AMED
    SEC Filings

    View All

    Lincoln National Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LINCOLN NATIONAL CORP (0000059558) (Filer)

    2/12/26 6:05:47 AM ET
    $LNC
    Life Insurance
    Finance

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    2/11/26 4:50:29 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Ascendis Pharma A/S

    20-F - Ascendis Pharma A/S (0001612042) (Filer)

    2/11/26 4:15:33 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $ACVA
    $ALNY
    $AMED
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 22, 2024 - FDA Roundup: March 22, 2024

    For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

    3/22/24 5:02:42 PM ET
    $SNAP
    $SRAX
    Computer Software: Programming Data Processing
    Technology
    Advertising
    Consumer Discretionary

    $ACLX
    $ACVA
    $ALNY
    $AMED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Advanced Drainage Systems Announces Proposed $500 Million Senior Notes Offering

    Advanced Drainage Systems, Inc. (NYSE:WMS) ("ADS" or the "Company"), a leading provider of innovative water management solutions in the stormwater and onsite wastewater industries, today announced that the Company intends, subject to market and other conditions, to commence an offering (the "Offering") of up to $500 million aggregate principal amount of senior unsecured notes due 2034 (the "Notes") in a private transaction exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). The Notes will be guaranteed by each of the Company's present and future direct and indirect domestic subsidiaries that guarantee its senior secured credit facility

    2/12/26 7:08:00 AM ET
    $WMS
    Containers/Packaging
    Consumer Discretionary

    Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

    Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company,"

    2/11/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    First Horizon Appoints Leilani Farol as Chief Information Security Officer

    MEMPHIS, Tenn., Feb. 11, 2026 /PRNewswire/ -- First Horizon (NYSE:FHN) announced today that Leilani Farol has joined the company as Senior Vice President, Chief Information Security Officer (CISO). In the CISO role, Farol will lead enterprise cybersecurity strategy and execution. She is responsible for continuing to strengthen the company's security posture to safeguard client data and privacy. "Leilani brings more than 25 years of leadership in information security, risk management and technology. We welcome her to the team in this critical role. By continuing to advance our

    2/11/26 10:59:00 AM ET
    $FHN
    Major Banks
    Finance

    $ACLX
    $ACVA
    $ALNY
    $AMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Smith Shane Patrick converted options into 5,243 shares, covered exercise/tax liability with 2,048 shares and returned $374,751 worth of shares to the company (1,377 units at $272.15), increasing direct ownership by 97% to 3,685 units (SEC Form 4)

    4 - Constellation Energy Corp (0001868275) (Issuer)

    2/11/26 6:13:53 PM ET
    $CEG
    Electric Utilities: Central
    Utilities

    EVP & CFO Eggers Daniel L. converted options into 44,601 shares, covered exercise/tax liability with 21,348 shares and returned $5,259,571 worth of shares to the company (19,326 units at $272.15), increasing direct ownership by 14% to 32,967 units (SEC Form 4)

    4 - Constellation Energy Corp (0001868275) (Issuer)

    2/11/26 6:13:52 PM ET
    $CEG
    Electric Utilities: Central
    Utilities

    SEC Form 4 filed by Officer Novotny Andrew R.

    4 - Constellation Energy Corp (0001868275) (Issuer)

    2/11/26 6:13:55 PM ET
    $CEG
    Electric Utilities: Central
    Utilities

    $ACLX
    $ACVA
    $ALNY
    $AMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Snap upgraded by Arete with a new price target

    Arete upgraded Snap from Neutral to Buy and set a new price target of $7.30

    2/10/26 7:58:39 AM ET
    $SNAP
    Computer Software: Programming Data Processing
    Technology

    Viatris upgraded by UBS with a new price target

    UBS upgraded Viatris from Neutral to Buy and set a new price target of $18.00

    2/9/26 6:59:24 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Snap upgraded by Stifel with a new price target

    Stifel upgraded Snap from Sell to Hold and set a new price target of $5.50

    2/6/26 8:05:59 AM ET
    $SNAP
    Computer Software: Programming Data Processing
    Technology

    $ACLX
    $ACVA
    $ALNY
    $AMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pinterest Inc.

    SC 13G/A - PINTEREST, INC. (0001506293) (Subject)

    12/6/24 10:11:26 AM ET
    $PINS
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Arcellx Inc.

    SC 13G - Arcellx, Inc. (0001786205) (Subject)

    11/22/24 4:12:28 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by MongoDB Inc.

    SC 13G/A - MongoDB, Inc. (0001441816) (Subject)

    11/15/24 10:35:42 AM ET
    $MDB
    Computer Software: Prepackaged Software
    Technology

    $ACLX
    $ACVA
    $ALNY
    $AMED
    Leadership Updates

    Live Leadership Updates

    View All

    First Horizon Appoints Leilani Farol as Chief Information Security Officer

    MEMPHIS, Tenn., Feb. 11, 2026 /PRNewswire/ -- First Horizon (NYSE:FHN) announced today that Leilani Farol has joined the company as Senior Vice President, Chief Information Security Officer (CISO). In the CISO role, Farol will lead enterprise cybersecurity strategy and execution. She is responsible for continuing to strengthen the company's security posture to safeguard client data and privacy. "Leilani brings more than 25 years of leadership in information security, risk management and technology. We welcome her to the team in this critical role. By continuing to advance our

    2/11/26 10:59:00 AM ET
    $FHN
    Major Banks
    Finance

    Pinterest Appoints Kecia Steelman to Board of Directors

    Pinterest, Inc. (NYSE:PINS) today announced that Kecia Steelman, President and Chief Executive Officer of Ulta Beauty, has been appointed to the company's Board of Directors, effective February 16, 2026. "Kecia is a seasoned executive with deep experience leading large-scale businesses and connecting consumers with brands they love," said Bill Ready, Chief Executive Officer of Pinterest. "Her track record of growing global businesses, building omnichannel experiences, and partnering closely with brands will be an asset as we continue to transform Pinterest into the leading visual discovery and AI-powered shopping platform, especially for Gen Z." Steelman joined Ulta Beauty in 2014 and h

    2/9/26 4:50:00 PM ET
    $PINS
    Computer Software: Programming Data Processing
    Technology

    Viatris Appoints Matthew J. Maletta as Chief Legal Officer

    Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 2026, to ensure a smooth transition

    2/3/26 8:30:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $ACVA
    $ALNY
    $AMED
    Financials

    Live finance-specific insights

    View All

    Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

    Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company,"

    2/11/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

    Schrödinger, Inc. (NASDAQ:SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed b

    2/11/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CRITEO REPORTS FOURTH QUARTER 2025 RESULTS

    Deployed $152 Million to Repurchase Shares in 2025 Remaining Share Buyback Authorization Increased up to $200 Million NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Criteo S.A. (NASDAQ:CRTO) ("Criteo" or the "Company"), the global platform connecting the commerce ecosystem, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter and Fiscal Year 2025 Financial Highlights: The following table summarizes our consolidated financial results for the three months and twelve months ended December 31, 2025: Three Months Ended Twelve Months Ended December 31 December 31 2025 2024 YoY Change 2025 2024 YoY Change (in millions, except EPS data) GAAP Resu

    2/11/26 7:00:00 AM ET
    $CRTO
    Advertising
    Consumer Discretionary